An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
This research is being done to find out if pemetrexed and cisplatin work better when given together with an experimental drug called MORAb-009 in patients with malignant pleural mesothelioma.
Checked against the public recordLast updated Sep 22, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Morphotek
- Interventions being studied
- Drug: MORAb-009 (Amatuximab); Drug: Pemetrexed; Drug: Cisplatin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Primary Inclusion Criteria: * Confirmed diagnosis of malignant pleural mesothelioma (MPM) with the following characteristics: unresectable disease (or otherwise not a candidate for curative surgery); epithelial type or biphasic (mixed) type with low sarcomatous content. * Measurable disease at Screening by computed tomography (CT)(or magnetic resonance imaging \[MRI\]). * KPS of greater than or equal to 70% at Screening. * Life expectancy of at least 3 months Primary Exclusion Criteria: * Sarcomatous type of mesothelioma * Prior systemic therapy or radiotherapy for MPM; local radiotherapy for symptom control (ie, non-curative intent) is permitted. * Confirmed presence of CNS tumor involvement. * Evidence of other active malignancy requiring treatment.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama, BirminghamBirmingham, Alabama
- University of California, San DiegoLa Jolla, California
- UCLA Medical Hematology & OncologyLos Angeles, California
- University of California, San FranciscoSan Francisco, California
- University of Colorado Cancer CenterAurora, Colorado
- Christiana Care Health SystemNewark, Delaware
- Emory University School of MedicineAtlanta, Georgia
- University of Chicago Medical CenterChicago, Illinois
- Johns Hopkins University--Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
- NIH/National Cancer InstituteBethesda, Maryland
- Columbia University Medical CenterNew York, New York
- Mary Babb Randolph Cancer CenterMorgantown, West Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2022. Always confirm current availability with the study team.